

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

April 17, 2023

ISSUE No.
1674

IN THIS ISSUE

COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old.....p 63

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65 (Issue 1674)

April 17, 2023

Take CME Exams

COVID-19 UPDATE

Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old

The FDA has expanded its Emergency Use Authorization (EUA) for the COVID-19 vaccine manufactured by Pfizer/BioNTech (*Comirnaty*) to permit use of the bivalent formulation (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children 6 months to 4 years old who completed the primary series with 3 doses of the monovalent formulation ≥ 2 months previously. The Pfizer bivalent vaccine had previously been authorized for use as a booster dose in persons ≥ 5 years old and as a third primary dose in children 6 months to 4 years old. Booster doses of the Moderna bivalent COVID-19 vaccine (*Spikevax*) for children 6 months to 5 years old were authorized earlier.^{1,2}

CLINICAL STUDIES – Expansion of the EUA was primarily based on the results of an unpublished immunogenicity trial (summarized in the FDA fact sheet) in which 60 children 6 months to 4 years old who had received 3 primary-series doses of the Pfizer monovalent vaccine were given a booster dose of the bivalent vaccine. Geometric mean neutralizing antibody titer levels against the BA.4/5 variant increased 8- to 9-fold in the month following booster immunization.³ Whether use of the booster dose reduces the incidence or severity of COVID-19 in children in this age group remains to be established.

ADVERSE EFFECTS – Adverse effects of the bivalent Pfizer vaccine in children 6 months to 4 years old have included injection-site reactions, fatigue, irritability, fever, chills, muscle and joint pain, headache,

vomiting, decreased appetite, muscle and joint pain, and lymphadenopathy. Severe allergic reactions and myocarditis/pericarditis have been reported.

RECOMMENDATIONS – For children 6 months to 4 years old receiving the Pfizer vaccine, CDC guidelines recommend a 3-dose primary series: two 3-mcg doses of the monovalent formulation given 3-8 weeks apart, followed by a 3-mcg dose of the bivalent vaccine given ≥ 8 weeks after the second monovalent dose. In those who have already completed a primary series with 3 doses of the monovalent vaccine, a 3-mcg booster dose of the bivalent formulation given ≥ 2 months after the third primary-series dose is recommended. Booster immunization is not currently recommended for children who received the bivalent vaccine as the final dose of their primary series.⁴ ■

1. COVID update: Bivalent vaccine booster doses authorized for children ≥ 5 years old. *Med Lett Drugs Ther* 2022; 64:e1.
2. COVID-19 update: Bivalent Pfizer and Moderna vaccines authorized for children ≥ 6 months old. *Med Lett Drugs Ther* 2022; 64:e209.
3. FDA. Fact sheet for health care providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine, bivalent (original and Omicron BA.4/BA.5) to prevent coronavirus disease 2019 (COVID-19). For 6 months through 4 years of age. March 14, 2023. Available at: <https://bit.ly/3HJhcUT>. Accessed March 30, 2023.
4. CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. March 16, 2023. Available at: <https://bit.ly/3KgPdxl>. Accessed March 30, 2023.

Additional Content Available Online: COVID-19 Tables/Charts

Please check our website for the latest information on COVID-19, including our continuously updated tables/charts on treatments and vaccines. Available at: www.medicalletter.org/drugs-for-covid-19.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

